GlassScriptPhysician profile
John S Lawall
NPI 1760436679
$391.01
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $212 · 2021: $19.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.38 | 2019-2020 | |
| Allergan, INC. | $57.31 | 2019-2021 | |
| Bausch Health US, LLC | $35.86 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.03 | 2019-2020 | |
| Promius Pharma LLC | $32.30 | 2019 | |
| Acadia Pharmaceuticals INC | $21.47 | 2020 | |
| Lilly USA, LLC | $19.62 | 2020 | |
| Genentech USA, INC. | $18.25 | 2019 | |
| Genzyme Corporation | $18.10 | 2020 | |
| Emd Serono, INC. | $16.08 | 2020 | |
| Abbvie INC. | $15.91 | 2020 | |
| Biogen, INC. | $15.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.97 | 2020 | |
| Assertio Therapeutics, INC. | $14.51 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.59 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lawall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.